NeuBase Therapeutics, Inc.
NBSE · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$1,821 | -$3,447 | -$4,093 | -$4,369 |
| Dep. & Amort. | $250 | $304 | $300 | $319 |
| Deferred Tax | $56 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $245 | $317 | $0 |
| Change in WC | -$196 | -$627 | -$26 | -$1,194 |
| Other Non-Cash | $1 | -$119 | $54 | $66 |
| Operating Cash Flow | -$2,003 | -$3,644 | -$3,448 | -$5,688 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | -$0 | -$13 | -$50 |
| Net Acquisitions | $0 | $0 | $9 | $0 |
| Inv. Purchases | $0 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $0 | $0 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $0 | -$0 | -$5 | -$50 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | -$158 | $4,576 | $1 | $30 |
| Stock Repurch. | -$0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$175 | $4,546 | -$88 | -$29 |
| Financing Cash Flow | -$175 | $4,546 | -$88 | -$29 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$2,177 | $902 | -$3,541 | -$5,766 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $14,747 | $13,845 | $17,386 | $23,153 |
| End Cash | $12,570 | $14,747 | $13,845 | $17,386 |
| Free Cash Flow | -$2,003 | -$3,644 | -$3,461 | -$5,738 |